US district court finds Zyprexa patent valid

EPP News Bureau - Hyderabad

The United States district court for the southern district of Indiana has issued an opinion following the completion of a trial on Eli Lilly’s US patent relating to Zyprexa and found the patent to be valid, said a press release issued by Dr Reddy’s Laboratories (DRL).

The court decision arises from a May 2001 suit filed by Eli Lilly against the company alleging patent infringement on the 382 compound patent listed on the Orange Book. The trial was completed in April 2004.

G V Prasad, CEO of DRL, said, ‘‘We are disappointed by the court decision and will appeal this decision to the federal circuit. Despite today’s adverse ruling, our strategy remains unchanged and we continue to make consistent progress towards building a sustainable generics business in the US’’.